NCT05273619View on ClinicalTrials.gov

Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

May 23, 2022

Primary Completion Date

July 13, 2022

Study Completion Date

July 29, 2022

Conditions
Common ColdAcute Respiratory InfectionInfluenza, Human
Interventions
DRUG

XC8, film-coated tablets, 10 mg

80 mg/day: 4 tablets (40 mg) twice a day

DRUG

Placebo

4 tablets twice a day

Trial Locations (6)

119571

Unimed-C Jsc, Moscow

153025

Ivanovo Kuvaev Clinical Hospital, Ivanovo

194000

EosMED JSC, Saint Petersburg

199178

OrKli Hospital LLC., Saint Petersburg

214031

Uromed LLC, Smolensk

610027

"Federal State Budgetary Educational Institution of Higher Education Kirov State Medical University of the Ministry of Healthcare of the Russian Federation", Kirov

All Listed Sponsors
lead

Valenta Pharm JSC

INDUSTRY